Resources

Artemisinin-based combination therapy is considered the gold standard treatment for malaria, but global demand has often outpaced production, and pricing has been volatile. With funding from the Bill & Melinda Gates Foundation, PATH and our partners set out to develop a new pharmaceutical manufacturing process to produce commercial volumes of high-quality, nonseasonal, and affordable artemisinin to supplement the plant-based supply. This poster, presented at the Bay Area World Malaria Day Symposium on April 25, 2014, presents key facts on malaria, the market for artemisinin, partner roles, and commercial production.

Part of the Technology Updates series, this fact sheet describes PATH’s work with diagnostic developers and stakeholders from around the world to develop a rapid, point-of-care diagnostic test for glucose-6 phosphate dehydrogenase (G6PD) deficiency. A reliable test for G6PD at the point of care is essential to malaria elimination strategies.

This brief provides policy recommendations to help Tanzania reduce the impacts of pneumonia and diarrhea and ensure all children have the chance to lead healthy lives.

This poster presentation from Digestive Disease Week 2014 summarizes the results of a study comparing the pharmacokinetic profiles of a single dose of 300 mg iOWH032 in healthy American volunteers, healthy Bangladeshi volunteers, and Bangladeshi cholera patients with severe diarrhea. In addition, the safety of iOWH032 was assessed in these different populations.

This fact sheet provides an overview of rotavirus disease and vaccines in Madagascar. It includes information about the tremendous burden of rotavirus diarrhea in Malagasy children, rotavirus diarrhea treatment and prevention strategies, and the effectiveness of rotavirus vaccines. It also lists countries that have introduced rotavirus vaccines into their national immunization programs.